IMR Press / EJGO / Volume 30 / Issue 1 / pii/2009018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists

Show Less
1 1st Department of Obstetrics and Gynaecology, Papageorgiou Hospital, Aristotle University of Thessaloniki (Greece)
Eur. J. Gynaecol. Oncol. 2009, 30(1), 82–84;
Published: 10 February 2009

Purpose of investigation: To investigate the attitude of Greek obstetrician-gynaecologists towards prescription of hormone thera­py to postmenopausal breast cancer survivors. Methods: An anonymous questionnaire was sent to members of the Hellenic Society of Obstetrics and Gynaecology with a hypothetical case and a series of relevant questions. Results: Three hundred valid answers were received. Hormone therapy would be prescribed to a breast cancer survivor by only 8%; 80% of these would prefer tibolone. In contrast, 92% would not prescribe hormone therapy; 97% would do so due to the risk of disease recurrence; 70% would not prescribe any alternative therapy, 21 % would prescribe CNS-active compounds and 7% SERMs. Conclusions: The vast majority of Greek obstetrician-gynaecologists would not prescribe hormone therapy for menopausal symptoms in breast cancer survivors due to the the­oretical risk of disease recurrence. Among those who would not prescribe hormone therapy, 21 % would opt to CNS-active com­pounds.

Breast cancer survivors
Menopausal hormone therapy
Estrogen-only therapy
Estrogen-progestogen combination
Back to top